The content on this site is intended for healthcare professionals only
During a press conference at ESMO 2012 in Vienna, Dr Carmen Criscitiello from the European Institute of Oncology in Milan, Italy, and colleagues report on an analysis of the different factors that may have affected the choice of surgery offered to patients in the NeoALTTO trial, which showed that the combination of paclitaxel, lapatinib and trastuzumab significantly increased the rate of tumour eradication (pathological complete response) compared to paclitaxel combined with either drug alone. The NeoALTTO trial was published in January this year.
Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
OncoAlert round up July 28th to August 3rd, 2023
ASCO 2023: Breast cancer research highlights
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
